ArticleProceedings of the National Academy of Sciences of the United States of America2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity.Cancer metastasis reviews · 2026Review
- Mutational signatures in hematological malignancies.Einstein (Sao Paulo, Brazil) · 2026Review
- Integrated single-cell and transcriptomic analysis of bone marrow-derived metastatic neuroblastoma reveals molecular mechanisms of metabolic reprogramming.Scientific reports · 2025Article
- Review
- Cancer brain metastasis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Oxphos targeting ofFrontiers in oncology · 2025Article
- Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025Review
- Progress in antitumor mechanisms and applications of phenformin (Review).Oncology reports · 2024Review
- Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression.Biomarker research · 2024Article
- Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.Pharmaceutics · 2023Article
- The Illustration of Altered Glucose Dependency in Drug-Resistant Cancer Cells.International journal of molecular sciences · 2023Review
- Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.MedComm · 2023Review
- Review
- Rho/SRF Inhibitor Modulates Mitochondrial Functions.International journal of molecular sciences · 2022Article
- Therapeutic and prognostic insights from the analysis of cancer mutational signatures.Trends in genetics : TIG · 2022Review
- MYCN in Neuroblastoma: "Old Wine into New Wineskins".Diseases (Basel, Switzerland) · 2021Review
- Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Krista M DaltonPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0003-0027-5453
Timothy L LochmannPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Konstantinos V FlorosPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0003-4916-2257
Marissa L CalbertPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0003-3005-8679
Richard KurupiPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
Giovanna T SteinCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129.
Joseph McClanaghanCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129.
Ellen MurchieCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129.ORCID 0000-0001-6562-5085
Regina K EganCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129.ORCID 0000-0002-2977-5702
Patricia GreningerCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129.ORCID 0000-0001-9110-7695
Mikhail DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0002-0086-8358
Sivapriya RamamoorthyDiscovery and Translational Sciences, Metabolon, Inc., Research Triangle Park, NC 27709.
Madhavi PuchalapalliDepartment of Pathology, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0002-9827-8697
Bin HuDepartment of Pathology, Virginia Commonwealth University, Richmond, VA 23298.
Lisa ShockDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0003-3791-4466
Jennifer KoblinskiDepartment of Pathology, Virginia Commonwealth University, Richmond, VA 23298.
John GlodPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Sosipatros A BoikosDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298.
Cyril H BenesCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA 02129; cyrilbenes@gmail.com acfaber@vcu.edu.
Anthony C FaberPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298; cyrilbenes@gmail.com acfaber@vcu.edu.
Virginia Commonwealth University · USHarvard University · USMetabolon (United States) · USNational Institutes of Health · US
Funding
Pediatric Oncology Branch Clinical Care and EducationZIEBC011516 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GLOD, JOHN · 2013 to 2025
$69.1MVirus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0MABT-199 based therapies to treat neuroblastomaR01CA215610 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Anthony Charles Faber · 2017 to 2026
$2.9MNeuroblastoma reliance on DNMT1 through amplified MYCNR01CA249219 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FABER, ANTHONY CHARLES · 2020 to 2023
$1.4MNCI NIH HHS P30 CA016059NCI NIH HHS R01 CA215610NCI NIH HHS R01 CA249219
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBasiginCell Line, TumorCell ProliferationElectron Transport Complex IGene AmplificationHumansMiceMitochondriaMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersNeuroblastomaN-Myc Proto-Oncogene ProteinPhenforminAZD3965BasiginBSG protein, humanElectron Transport Complex IMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersMYCN protein, humanN-Myc Proto-Oncogene ProteinPhenforminPyrimidinonesSymportersThiophenesapoptosislactatemetabolomicsMYCNneuroblastoma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.